Table 3.
Univariate analysis (p log-rank) of overall survival
| N | mOS | Lower limit | Upper limit | HR | 95% CI | p value | |
|---|---|---|---|---|---|---|---|
| Reflect-in | 110 | 15.6 | 10.7 | 20.5 | 0.55 | 0.38–0.81 | 0.002 |
| Reflect-out | 95 | 10.2 | 7.9 | 12.5 | |||
| Child-Pugh A | 160 | 13.8 | 11.3 | 16.4 | 0.42 | 0.27–0.63 | <0.001 |
| Child-Pugh B | 45 | 6.1 | 4.6 | 7.6 | |||
| ALBI 1 | 70 | 19.9 | 10.2 | 29.7 | 0.001 | ||
| ALBI 2 | 116 | 11.2 | 7.2 | 15.1 | 2.07 | 1.34–3.19 | 0.001 (1 vs. 2) |
| ALBI 3 | 19 | 7.1 | 6.1 | 8.0 | 2.80 | 1.43–5.52 | 0.003 (1 vs. 3) |
| Age <69 years | 98 | 13.1 | 11.2 | 15.2 | 0.99 | 0.68–1.48 | 0.979 |
| Age ≥69 years | 107 | 10.7 | 7.6 | 13.8 | |||
| Male | 167 | 12.6 | 9.6 | 15.9 | 0.99 | 0.59–1.65 | 0.976 |
| Female | 38 | 12.3 | 10.2 | 14.4 | |||
| ECOG 0 | 85 | 13.3 | 10.5 | 15.9 | |||
| ECOG 1 | 91 | 12.5 | 8.9 | 16.1 | 1.13 | 0.75–1.70 | 0.563 (0 vs. 1) |
| ECOG 2 | 23 | 6.4 | 2.9 | 9.9 | 2.17 | 1.22–3.85 | 0.005 (0 vs. 2) |
| Etiology viral hepatitis | 54 | 13.2 | 9.0 | 17.3 | 0.80 | 0.51–1.24 | 0.313 |
| Etiology other than viral hepatitis | 151 | 12.6 | 10.3 | 14.9 | |||
| Previous treatment | 148 | 12.7 | 7.1 | 18.4 | 0.73 | 0.48–1.10 | 0.126 |
| No previous treatment (no medication and | 57 | 12.7 | 10.2 | 15.2 | |||
| procedure) | |||||||
| Posttreatment anticancer medication | 88 | 15.9 | 10.5 | 21.3 | 0.45 | 0.30–0.66 | <0.001 |
| No posttreatment anticancer medication | 112 | 8.6 | 5.9 | 11.2 | |||
| Macrovascular invasion | 86 | 8.8 | 7.0 | 10.6 | 1.78 | 1.22–2.60 | 0.003 |
| No macrovascular invasion | 118 | 15.6 | 12.9 | 18.2 | |||
| Invasion of main branch of portal vein | 47 | 10.2 | 7.3 | 13.0 | 1.52 | 0.97–2.38 | 0.063 |
| No invasion of main branch of portal vein | 154 | 13.8 | 11.0 | 16.6 | |||
| Extrahepatic spread | 80 | 12.5 | 8.9 | 16.1 | 1.06 | 0.72–1.55 | 0.77 |
| No extrahepatic spread | 123 | 12.7 | 10.5 | 14.9 | |||
| AFP ≥200 ng/mL | 87 | 10.7 | 7.4 | 13.9 | 1.74 | 1.19–2.54 | 0.004 |
| AFP <200 ng/mL | 115 | 15.6 | 12.6 | 18.7 | |||
| BCLC B | 58 | 13.8 | 9.7 | 18.0 | 1.36 | 0.88–2.08 | 0.161 |
| BCLC C | 141 | 11.3 | 8.6 | 14.1 | |||
| Reduced lenvatinib dose | 114 | 10.4 | 7.8 | 13.1 | 1.36 | 0.93–1.99 | 0.111 |
| Standard lenvatinib dose | 89 | 13.8 | 11.1 | 16.5 | |||
| Radiologic response | 48 | 23.9 | 15.4 | 32.4 | 0.40 | 0.23–0.68 | <0.001 |
| No radiologic response | 112 | 10.2 | 7.6 | 12.7 | |||
| Radiologic disease control | 117 | 17.8 | 4.7 | 9.2 | 0.24 | 0.15–0.38 | <0.001 |
| No radiologic disease control | 43 | 7.0 | 13.7 | 21.9 | |||
| AFP response | 57 | 14.5 | 10.1 | 18.8 | 0.83 | 0.54–1.28 | 0.391 |
| No AFP response | 137 | 12.6 | 10.2 | 15.1 |
Univariate analysis (p log-rank) of overall survival in months. N, number of patients with available data; median overall survival with lower and upper 95% CI level and p value.